ARTV · Artiva Biotherapeutics

The thesis

Artiva Biotherapeutics is more likely to lag the S&P 500 over the next three months. The shares now trade on a board strategic review with no set date, and its outcome (merger, asset sale or licensing, or liquidation) decides what $319.1 million of cash is worth to holders. The company says it will not update the market until the board approves a course of action, the process ends or disclosure is legally required.

Artiva discontinued its natural killer (NK) cell therapy AlloNK on 27 October 2026, cut about 94% of its workforce and began the review with Leerink Partners as financial advisor. The Form 10-Q for the quarter ended 30 September 2026 confirms $61.2 million in cash and cash equivalents plus $257.9 million in short-term investments, about $319.1 million in total, against total liabilities of $22.3 million.

An amended 8-K reported on 9 November 2026 estimates $10 million to $15 million for clinical trial close-out and contract termination and $17 million to $20 million for the workforce reduction. Artiva expects most of those costs in the fourth quarter of 2026 and expects to finish the workforce cut in the first quarter of 2027.

The shares closed at $3.96 on 12 November 2026, down 65.4% over three months. That price reflects the 27 October 2026 discontinuation, the fatal safety events behind it and the $319.1 million cash balance reported in the 10-Q filed 9 November 2026.

Bullish and bearish views on Artiva Biotherapeutics, Inc.

The bull case on Artiva Biotherapeutics, Inc. (ARTV), in brief: reported cash is large against liabilities. The bear case: the lead asset is stopped.

Bull case

• Reported cash is large against liabilities. The 10-Q reports $319.1 million in cash, cash equivalents and investments at 30 September 2026, the same total Artiva gave in its 27 October 2026 8-K. Total liabilities were $22.3 million, including about $9.2 million of operating lease liabilities.
• Wind-down costs now have a range. The amended 8-K gives $10 million to $15 million for trial close-out and contract termination and $17 million to $20 million for workforce reduction (reported 9 November 2026).
• A formal process is underway. The board is reviewing a merger, business combination, sale or licensing of assets, or dissolution and liquidation, with Leerink Partners advising (8-K, 27 October 2026). An announced transaction would give the shares a priced outcome.
• The share price has already fallen sharply. The adjusted close was $11.45 on 14 August 2026 and $3.96 on 12 November 2026, so the move since the discontinuation has been steep.

Bear case

• The lead asset is stopped. AlloNK development is discontinued and the planned Phase 3 trial in about 150 refractory rheumatoid arthritis patients will not start (press release, 27 October 2026). Artiva has no active clinical program.
• Two patients died. One Phase 2a patient died of leukoencephalopathy after chemotherapy conditioning, judged likely related to fludarabine-associated neurotoxicity by the investigator and an independent safety review. A second patient died about two months after starting treatment, cause undetermined (press release, 27 October 2026).
• Executives sold after the announcement. SEC Form 4 filings show CEO Fred Aslan sold 62,178 shares at $4.18 on 2 November 2026, and three other officers also sold at $4.18 the same day. Aslan had sold 23,463 shares at $7.20 on 6 October 2026 under a Rule 10b5-1 trading plan.
• Analysts have moved to neutral ratings. Wedbush, Needham and Jefferies each downgraded the shares to Neutral or Hold after the announcement, per Benzinga headlines dated through 30 October 2026.
• Cash is still being spent. Artiva reported a net loss of $28.8 million, or $0.56 per share, for the quarter ended 30 September 2026 (10-Q). The wind-down charges come on top of ordinary spending until the headcount reduction completes.
• Process outcomes can leave less for holders. Liquidation, a reverse merger that issues new shares, or an asset sale at a low price are all listed outcomes, and the company gave no assurance of any transaction. A law firm announced an investigation of Artiva on 10 November 2026, and litigation would cost cash.

Price setup

The shares closed at $3.96 on 12 November 2026, down from $4.22 on 9 November 2026 and $4.15 on 6 November 2026. The closes from 5 November to 12 November 2026 sit in a narrow range between $3.96 and $4.22.

The 50-day average of $6.80 and the 200-day average of $8.00 (adjusted closes, as of 12 November 2026) both sit far above the last close. The 52-week intraday high is $14.53, set on 20 April 2026. The 52-week closing low is $3.07, set on 10 December 2025.

The price moves on the company's cash and the odds of a distribution, not on earnings or clinical news. Artiva reported 49,432,351 common shares outstanding at 30 October 2026 (10-Q), so cash can be compared directly with the share count once the board announces a course of action. No earnings date falls inside the next 30 days, and the company cancelled its data presentation and investor webcast.

Catalysts ahead

• Undated: Strategic review outcome: merger, asset sale or licensing, or dissolution and liquidation. This decides what the shares are worth against the $319.1 million cash balance; the company will update only when the board approves a course of action.
• ~March 2027 (est.): Annual report covering the fourth quarter of 2026. Shows the wind-down charges actually booked against the $27 million to $35 million combined estimate and the cash that remains.

What would change the view

A daily close above $5.29, which would show the market pricing Artiva's cash well above its recent range and the shares leading the S&P 500. An announced transaction valuing the shares above $5.29 would also prove the call wrong.

What it trades with

ARTV trades on company-specific news and not on sector moves. The shares no longer track the AlloNK clinical story, since the program is discontinued. The closest comparisons are other clinical-stage biotechs that ended a lead program and ran strategic reviews, where outcomes ranged from reverse mergers to cash distributions. The sample of such outcomes here is too small to draw a conclusion about which one applies to Artiva.